Skip to main content
ARDELYX, INC. logo

ARDELYX, INC. — Investor Relations & Filings

Ticker · ARDX ISIN · US0396971071 LEI · 549300F542QR4SXHCY32 US Manufacturing
Open in API
Filings indexed 1,078 across all filing types
Latest filing 2017-11-02 Major Shareholding Noti…
Country US United States of America
Listing US ARDX

About ARDELYX, INC.

https://www.ardelyx.com/

Ardelyx, Inc. is a biopharmaceutical company that discovers, develops, and commercializes first-in-class medicines to address unmet medical needs. The company's primary therapeutic areas of focus are cardiorenal and gastrointestinal diseases. Its key commercial product is XPHOZAH® (tenapanor), a novel mechanism therapy for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Ardelyx also develops treatments for Irritable Bowel Syndrome with Constipation (IBS-C), aiming to advance patient care through its portfolio of innovative therapies.

Recent filings

Filing Released Lang Actions
13G
Major Shareholding Notification
2017-11-02 English
FORM 4
Director's Dealing
2017-10-27 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes an Item 7.01 Regulation FD Disclosure referencing an attached corporate presentation (Exhibit 99.1), and Item 8.01 Other Events describing positive Phase 3 clinical trial results for a drug. There are no comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The main content is a corporate presentation and clinical trial update, which aligns with an Investor Presentation (IP). The document is not merely an announcement of a report but includes substantive information about the clinical trial results and corporate presentation. Therefore, the best classification is Investor Presentation (IP).
2017-10-11 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically details the departure of a Vice President, Corporate Controller and Chief Accounting Officer, Bryan Shaw, and the appointment of Mark Kaufmann as Principal Accounting Officer. This is a clear announcement of changes in senior management. The document length is 3361 characters, which is relatively short and focused on management changes. There is no financial data or report attached, so it is not an Annual Report or Interim Report. The key section is Item 5.02, which relates to departure and appointment of officers. Therefore, the document fits the category of Board/Management Information (MANG).
2017-09-18 English
FORM 4 SUBMISSION
Director's Dealing
2017-08-31 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-08-31 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.